InvestorsHub Logo
Followers 25
Posts 5871
Boards Moderated 0
Alias Born 03/15/2014

Re: pointofreturn post# 9632

Sunday, 06/29/2014 5:49:57 PM

Sunday, June 29, 2014 5:49:57 PM

Post# of 140474
This may be an "outlier" Point (and it is Pharma) but Merck is bucking up almost $4 bil (~240%) for Idenix and a promising compound in the Hep C market (which I believe is upwards of $20 billion annually). There are other players in the industry too! If we are entering a consolidation phase in med/pharma/biotech, 200 to 300% premiums for M/As may become more common.